Estudios clínicos con inhibidores de la PCSK9

Los inhibidores de la enzima proproteína convertasa subtilisina kexina tipo 9 (PCSK9) constituyen una herramienta terapéutica novedosa para el selecto grupo de pacientes de muy alto riesgo en quienes no se han alcanzado las metas de colesterol LDL. Han demostrado tener efecto hipolipemiante potente...

Full description

Bibliographic Details
Published in:	Revista Colombiana de Cardiología
Main Author:	Rafael Campo
Format:	Article
Language:	English
Published:	Permanyer 2017-11-01
Subjects:	iPCSK9 Prevención secundaria Hipercolesterolemia familiar Intolerancia a estatinas
Online Access:	http://www.sciencedirect.com/science/article/pii/S0120563317301912

Similar Items

Indicaciones para el uso de los inhibidores de la PCSK9
by: Rodrigo Alonso, et al.
Published: (2017-11-01)

Efficacy and safety of the PCSK9 inhibitors in the treatment of dyslipidemia in chronic kidney disease
by: Borja Quiroga, et al.
Published: (2020-09-01)

Inhibitorii PCSK9 – un nou medicament cu efect de reducere a lipidelor
by: Carolina Dumanschi
Published: (2019-03-01)

Guía de práctica clínica para la prevención, detección temprana, diagnóstico, tratamiento y seguimiento de las dislipidemias: tratamiento farmacológico con estatinas
by: Oscar Múñoz, et al.
Published: (2015-01-01)

Eficacia y seguridad de la atorvastatina en dosis altas en pacientes con enfermedad renal crónica estadio 5 en terapia de diálisis peritoneal
by: César A. Restrepo, et al.
Published: (2014-11-01)

Estatinas e a Coenzima Q10
by: Teresa Alves, et al.
Published: (2024-01-01)

Hipercolesterolemia familiar heterocigota en manejo con anti–PCSK9
by: Mauricio Duque, et al.
Published: (2017-09-01)

PCSK9-antibodies fail to block PCSK9-induced inflammation in macrophages and cannot recapitulate protective effects of PCSK9-deficiency in experimental myocardial infarction
by: Simon Rauterberg, et al.
Published: (2025-01-01)

PCSK9: BIOLOGICAL ACTIVITY REGULATION AND CONNECTION WITH LIPID AND CARBOHYDRATE METABOLISM
by: A O Averkova
Published: (2017-09-01)

Familial hyperlipidemia: Resolving a case using evidence-based medicine
by: Edison Benavides-Hernández, et al.
Published: (2011-03-01)

Insight into the Evolving Role of PCSK9
by: Mateusz Maligłówka, et al.
Published: (2022-03-01)

Evolocumab y sus posibles beneficios para una población en riesgo
by: Jimena Araya Vargas, et al.
Published: (2016-11-01)

PCSK9 in T-cell function and the immune response
by: Yuying Wang, et al.
Published: (2024-12-01)

Respuesta supraóptima a los inhibidores de PCSK-9: ¿es obligatorio darlos cada 2 semanas? A propósito de un caso
by: G. A. Parra, et al.
Published: (2020-04-01)

PCSK9 - A New and Potent Approach to Lowering Cholesterol
by: Thomas F. Whayne Jr.
Published: (2013-05-01)

The association between circulatory, local pancreatic PCSK9 and type 2 diabetes mellitus: The effects of antidiabetic drugs on PCSK9
by: Fengyuan Lu, et al.
Published: (2023-09-01)

The discovery of PCSK9 as a pivotal point in the prevention of cardiovascular disease
by: Alexander C. Razavi, et al.
Published: (2025-12-01)

The effect of PCSK9 immunization on the hepatic level of microRNAs associated with PCSK9/LDLR pathway.
by: Sarina Ataei, et al.
Published: (2023-01-01)

Aplicación del puntaje de riesgo poligénico de colesterol-LDL elevado de seis SNP en población argentina con fenotipo de hipercolesterolemia familiar
by: Virginia Bañares, et al.
Published: (2024-10-01)

PCSK9 Associated Promoter Methylation Status in Patients with Hyperlipidemia
by: Samaneh Bahrami, et al.
Published: (2021-08-01)

The Impact of PCSK9 on Diabetic Cardiomyopathy: Mechanisms and Implications
by: Haixia Wang, et al.
Published: (2025-08-01)

PCSK9 as a Target for Development of a New Generation of Hypolipidemic Drugs
by: Nikolay Kuzmich, et al.
Published: (2022-01-01)

Gain of function variants in PCSK9 gene in high risk patients after myocardial infarction with increased lipoprotein (a) values and treated with statins
by: Sabina Ugovšek, et al.
Published: (2025-07-01)

Circulating PCSK9 Linked to Dyslipidemia in Lebanese Schoolchildren
by: Yara Azar, et al.
Published: (2022-05-01)

Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance
by: Konstantinos Koskinas, et al.
Published: (2016-07-01)

LDL Cholesterol, Statins And PCSK 9 Inhibitors
by: Sanjiv Gupta
Published: (2015-09-01)

Effect of atorvastatin and rosuvastatin on the PCSK9 blood concentration in statin-naive patients with atherosclerosis
by: A. Yu. Filatova, et al.
Published: (2019-06-01)

PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression
by: Maram H. Abduljabbar
Published: (2024-11-01)

Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) consensus on the usage of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
by: Ashraf Reda, et al.
Published: (2020-05-01)

Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) to tackle central nervous system diseases: role as a promising approach
by: Xiaoxiao Zheng, et al.
Published: (2025-07-01)

Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis
by: Vittoria Cammisotto, et al.
Published: (2022-03-01)

Role of PCSK9 inhibitors in the management of dyslipidaemia
by: Tiny Nair
Published: (2024-03-01)

Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis
by: Emily Punch, et al.
Published: (2022-02-01)

PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis
by: Ding-Qiang Chen, et al.
Published: (2024-07-01)

Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)
by: Xiang Zhang, et al.
Published: (2020-05-01)

Conditional knockdown of hepatic PCSK9 ameliorates high-fat diet-induced liver inflammation in mice
by: Xue-Ying Zhang, et al.
Published: (2025-02-01)

VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys
by: Madeline M. Vroom, et al.
Published: (2024-02-01)

Potential dual inhibitors of PCSK-9 and HMG-R from natural sources in cardiovascular risk management
by: Mohd Waiz, et al.
Published: (2022-01-01)

Modulation of atherogenesis biomarkers by PCSK9 inhibitors in Lp(a)-stimulated human coronary artery endothelial cells
by: Rahayu Zulkapli, et al.
Published: (2025-07-01)

Elevated circulating PCSK9 level is associated with 28-day mortality in patients with sepsis: a prospective cohort study
by: Yuanlu Shu, et al.
Published: (2023-10-01)